Therapeutic host-directed strategies to improve outcome in tuberculosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
WHO. Global tuberculosis report 2017. http://www.who.int/tb/publications/global_report/en/. Accessed 28 April 2018.
WHO. WHO end TB strategy. http://www.who.int/tb/post2015_strategy/en/. Accessed 28 April 2018.
Huang, 2017, Protective immunity against tuberculosis: what does it look like and how do we find it?, Curr. Opin. Immunol., 48, 44, 10.1016/j.coi.2017.08.001
Maertzdorf, 2010, Human gene expression profiles of susceptibility and resistance in tuberculosis, Genes & Immunity, 12, 15, 10.1038/gene.2010.51
Turner, 2017, Tuberculosis infectiousness and host susceptibility, J. Infect. Dis., 216, S636, 10.1093/infdis/jix361
Roberts, T., Beyers, N., Aguirre, A. & Walzl, G. Immunosuppression during Active Tuberculosis Is Characterized by Decreased Interferon-γ Production and CD25 Expression with Elevated Forkhead Box P3, Transforming Growth Factor-β, and Interleukin-4 mRNA Levels. J. Infect. Dis. 195, 870–878 (2007).
Malherbe, 2016, Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure, Nat. Med., 22, 1094, 10.1038/nm.4177
Barry, 2009, The spectrum of latent tuberculosis: rethinking the biology and intervention strategies, Nature Reviews Microbiology, 7, 845, 10.1038/nrmicro2236
Ricciotti, 2011, Prostaglandins and Inflammation, Arterioscler. Thromb. Vasc. Biol., 31, 986, 10.1161/ATVBAHA.110.207449
Moreno, 2002, The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis, Immunology, 106, 257, 10.1046/j.1365-2567.2002.01403.x
Kroesen, V. M. et al. Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review. Front. Immunol. 8 1–9 (2017).
Dutta, 2007, Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice, Int. J. Antimicrob. Agents, 30, 336, 10.1016/j.ijantimicag.2007.04.016
Byrne, 2007, Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis, J. Antimicrob. Chemother., 59, 313, 10.1093/jac/dkl486
Maitra, 2016, Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs, Br. Med. Bull., 118, 138, 10.1093/bmb/ldw019
Mai, 2018, A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults, eLife, 7, e33478, 10.7554/eLife.33478
Misra, 2010, A study of cytokines in tuberculous meningitis: Clinical and MRI correlation, Neuroscience Letters, 483, 6, 10.1016/j.neulet.2010.07.029
Wu, 2017, Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study, BMC Pulm. Med., 17, 82, 10.1186/s12890-017-0425-3
Mayer-Barber, 2014, Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk, Nature, 511, 99, 10.1038/nature13489
Bafica, 2005, Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production, J. Clin. Invest., 115, 1601, 10.1172/JCI23949
Cohen, 2015, Randomized, double-blind, comparative-effectiveness study comparing pulsed radiofrequency to steroid injections for occipital neuralgia or migraine with occipital nerve tenderness, PAIN, 156, 2585, 10.1097/j.pain.0000000000000373
de Gans, J. & van de Beek, D. Dexamethasone in Adults with Bacterial Meningitis. N. Engl. J. Med. 347, 1549–1556 (2002).
Kadhiravan, T. & Deepanjali, S. Role of corticosteroids in the treatment of tuberculosis: an evidence-based update. Indian J. Chest Dis. Allied Sci.52, 153–158 (2010).
Biddie, 2011, Dynamic regulation of glucocorticoid signalling in health and disease, Rheumatology, 51, 403, 10.1093/rheumatology/ker215
Ramamoorthy, 2016, Corticosteroids: mechanisms of action in health and disease, Rheum. Dis. Clin., 42, 15, 10.1016/j.rdc.2015.08.002
Dooley, 1997, Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature, Clin. Infect. Dis., 25, 872, 10.1086/515543
Horne, 1960, Prednisolone in treatment of pulmonary tuberculosis: a controlled trial, Br. Med. J., 2, 1751, 10.1136/bmj.2.5215.1751
Lavers, 1959, The use of prednisone in primary tuberculosis in children, Tubercle, 40, 173, 10.1016/S0041-3879(59)80036-2
Meintjes, 2010, Randomized placebo-controlled trial of prednisone for paradoxical TB-associated immune reconstitution inflammatory syndrome, AIDS Lond. Engl., 24, 2381, 10.1097/QAD.0b013e32833dfc68
Kumarvelu, 1994, Randomized controlled trial of dexamethasone in tuberculous meningitis, Tuber. Lung Dis. J. Int. Union Tuberc. Lung Dis., 75, 203, 10.1016/0962-8479(94)90009-4
Mayosi, B. M. et al. Prednisolone and Mycobacterium indicus pranii in Tuberculous Pericarditis. N. Engl. J. Med.371, 1121–1130 (2014).
Xie, 2017, The efficacy and safety of adjunctive corticosteroids in the treatment of tuberculous pleurisy: a systematic review and meta-analysis, Oncotarget, 8, 83315, 10.18632/oncotarget.18160
Critchley, 2013, Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis, Lancet Infect. Dis., 13, 223, 10.1016/S1473-3099(12)70321-3
Page, 2011, Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases, 391
Maiga, 2012, Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model, PLoS ONE, 7, e30749, 10.1371/journal.pone.0030749
Maiga, 2015, Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis, Antimicrob. Agents Chemother., 59, 7888, 10.1128/AAC.02145-15
Subbian, 2016, Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model, EBioMedicine, 4, 104, 10.1016/j.ebiom.2016.01.015
Subbian, 2011, Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology, Am. J. Pathol., 179, 289, 10.1016/j.ajpath.2011.03.039
Serafini, 2006, Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function, J. Exp. Med., 203, 2691, 10.1084/jem.20061104
Cazzola, 2015, Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis, Eur. Respir. Rev., 24, 451, 10.1183/16000617.00002215
Amaral, 2016, N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions, BMC Microbiol., 16, 251, 10.1186/s12866-016-0872-7
Teskey, 2018, The synergistic effects of the glutathione precursor, NAC and first-line antibiotics in the granulomatous response against Mycobacterium tuberculosis, Front. Immunol., 9, 2069, 10.3389/fimmu.2018.02069
Mahakalkar, 2017, N-acetylcysteine as an add-on to directly observed therapy short-I therapy in fresh pulmonary tuberculosis patients: a randomized, placebo-controlled, double-blinded study, Perspect. Clin. Res., 8, 132, 10.4103/2229-3485.210450
Cheng, 2016, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity, Eur. Respir. J., 48, PA2716
Baniasadi, 2010, Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity, European Journal of Gastroenterology & Hepatology, 22, 1235, 10.1097/MEG.0b013e32833aa11b
Vilchèze, 2017, Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis, Proc. Natl. Acad. Sci. USA, 114, 4495, 10.1073/pnas.1704376114
Yogalingam, 2008, Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components, J. Biol. Chem., 283, 35941, 10.1074/jbc.M804543200
Bruns, 2012, Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages, J. Immunol., 189, 4069, 10.4049/jimmunol.1201538
Napier, 2015, Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity, PLoS Pathog., 11, e1004770, 10.1371/journal.ppat.1004770
Napier, 2011, Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis, Cell Host Microbe, 10, 475, 10.1016/j.chom.2011.09.010
Steiger, 2016, Imatinib triggers phagolysosome acidification and antimicrobial activity against Mycobacterium bovis bacille Calmette–Guérin in glucocorticoid-treated human macrophages, J. Immunol., 197, 222, 10.4049/jimmunol.1502407
Sogi, 2017, The tyrosine kinase inhibitor gefitinib restricts Mycobacterium tuberculosis growth through increased lysosomal biogenesis and modulation of cytokine signaling, ACS Infect. Dis., 3, 564, 10.1021/acsinfecdis.7b00046
Hussain, 2019, Nilotinib: a tyrosine kinase inhibitor mediates resistance to intracellular Mycobacterium Via regulating autophagy, Cells, 8, 506, 10.3390/cells8050506
Zheng, 2017, Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden, Glob. Health Action, 10, 1264702, 10.1080/16549716.2016.1264702
Stevenson, C. R. et al. Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7, 234 (2007).
Hsieh, C.-H., He, C.-T., Lee, C.-H., Wu, L.-Y. & Hung, Y.-J. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism56, 1087–1092 (2007).
Marupuru, 2017, Protective effect of metformin against tuberculosis infections in diabetic patients: an observational study of south Indian tertiary healthcare facility, The Brazilian Journal of Infectious Diseases, 21, 312, 10.1016/j.bjid.2017.01.001
Hirst, 2012, Quantifying the effect of metformin treatment and dose on glycemic control, Diabetes Care, 35, 446, 10.2337/dc11-1465
Lee, 2018, The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus, Korean J. Intern. Med., 33, 933, 10.3904/kjim.2017.249
Martinez, N., Ketheesan, N., West, K., Vallerskog, T. & Kornfeld, H. Impaired Recognition of Mycobacterium tuberculosis by Alveolar Macrophages From Diabetic Mice. J. Infect. Dis. 214, 1629–1637 (2016).
Martens, 2007, Tuberculosis Susceptibility of Diabetic Mice, American Journal of Respiratory Cell and Molecular Biology, 37, 518, 10.1165/rcmb.2006-0478OC
Lopez-Lopez, N. et al. Type-2 diabetes alters the basal phenotype of human macrophages and diminishes their capacity to respond, internalise, and control Mycobacterium tuberculosis. Mem. Inst. Oswaldo Cruz 113, e170326–e170326 (2018).
Restrepo, 2014, Phagocytosis via complement or Fc-Gamma receptors is compromised in monocytes from type 2 diabetes patients with chronic hyperglycemia, PLoS ONE, 9, e92977, 10.1371/journal.pone.0092977
Zhou, 2001, Role of AMP-activated protein kinase in mechanism of metformin action, J. Clin. Invest., 108, 1167, 10.1172/JCI13505
Kukidome, 2005, Activation of AMP-Activated Protein Kinase Reduces Hyperglycemia-Induced Mitochondrial Reactive Oxygen Species Production and Promotes Mitochondrial Biogenesis in Human Umbilical Vein Endothelial Cells, Diabetes, 55, 120, 10.2337/diabetes.55.01.06.db05-0943
Singhal, 2014, Metformin as adjunct antituberculosis therapy, Sci. Transl. Med., 6, 263ra159, 10.1126/scitranslmed.3009885
Vashisht, 2015, Metformin as a potential combination therapy with existing front-line antibiotics for Tuberculosis, J. Transl. Med., 13, 10.1186/s12967-015-0443-y
Degner, 2017, Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment, Clin. Infect. Dis., 66, 198, 10.1093/cid/cix819
Pan, 2018, The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment, Chest, 153, 1347, 10.1016/j.chest.2017.11.040
Lachmandas, 2019, Metformin alters human host responses to Mycobacterium tuberculosis in healthy subjects, J. Infect. Dis., 220, 139, 10.1093/infdis/jiz064
Adak, 2018, A reappraisal on metformin, Regul. Toxicol. Pharmacol., 92, 324, 10.1016/j.yrtph.2017.12.023
Tukvadze, 2015, High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial, Am. J. Clin. Nutr., 102, 1059, 10.3945/ajcn.115.113886
Wejse, 2009, Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial, Am. J. Respir. Crit. Care Med., 179, 843, 10.1164/rccm.200804-567OC
Yuk, 2009, Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin, Cell Host Microbe, 6, 231, 10.1016/j.chom.2009.08.004
Liu, 2007, Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin, J. Immunol., 179, 2060, 10.4049/jimmunol.179.4.2060
Lawson, 2010, Randomized controlled trial of zinc and vitamin A as co-adjuvants for the treatment of pulmonary tuberculosis, Trop. Med. Int. Health, 15, 1481, 10.1111/j.1365-3156.2010.02638.x
Villamor, 2008, A trial of the effect of micronutrient supplementation on treatment outcome, T cell counts, morbidity, and mortality in adults with pulmonary tuberculosis, J. Infect. Dis., 197, 1499, 10.1086/587846
Iannitti, T. & Palmieri, B. Clinical and Experimental Applications of Sodium Phenylbutyrate. Drugs RD11, 227–249 (2011).
Peña-Quintana, L., Llarena, M., Reyes-Suárez, D. & Aldámiz-Echevarria, L. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives. Patient Prefer. Adherence11, 1489–1496 (2017).
Aibana, 2017, Impact of vitamin A and carotenoids on the risk of tuberculosis progression, Clin. Infect. Dis., 65, 900, 10.1093/cid/cix476
Coussens, 2015, High-dose vitamin D3 reduces deficiency caused by low UVB exposure and limits HIV-1 replication in urban Southern Africans, Proc. Natl. Acad. Sci. USA, 112, 8052, 10.1073/pnas.1500909112
Rekha, 2015, Phenylbutyrate induces LL-37-dependent autophagy and intracellular killing of Mycobacterium tuberculosis in human macrophages, Autophagy, 11, 1688, 10.1080/15548627.2015.1075110
Mahoney, 2015, The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma, Clin. Ther., 37, 764, 10.1016/j.clinthera.2015.02.018
Dyck, 2017, Immune checkpoints and their inhibition in cancer and infectious diseases, Eur. J. Immunol., 47, 765, 10.1002/eji.201646875
Jayaraman, 2016, TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection, PLoS Pathog., 12, e1005490, 10.1371/journal.ppat.1005490
Kirman, 1999, CTLA-4 blockade enhances the immune response induced by mycobacterial infection but does not lead to increased protection, Infect. Immun., 67, 3786, 10.1128/IAI.67.8.3786-3792.1999
Jurado, 2008, Programmed death (PD)-1: PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis, J. Immunol., 181, 116, 10.4049/jimmunol.181.1.116
Reljic, R., Paul, M. J. & Arias, M. A. Cytokine therapy of tuberculosis at the crossroads. Expert Rev. Respir. Med.3, 53–66 (2009).
Rivero-Lezcano, 2008, Cytokines as Immunomodulators in Tuberculosis Therapy, Recent Patents on Anti-Infective Drug Discovery, 3, 168, 10.2174/157489108786242332
Fujita, 2016, Anti-PD1 antibody treatment and the development of acute pulmonary tuberculosis, J. Thorac. Oncol., 11, 2238, 10.1016/j.jtho.2016.07.006
Benmerzoug, 2018, GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection, Sci. Rep., 8, 8652, 10.1038/s41598-018-26984-3
Kumar, N. P., Moideen, K., Banurekha, V. V., Nair, D. & Babu, S. Plasma proinflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis. Open Forum Infect. Dis. 6, 1–8 (2019).
Holland, 1994, Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma: a preliminary report, N. Engl. J. Med., 330, 1348, 10.1056/NEJM199405123301904
Dawson, 2009, Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis, PLoS ONE, 4, e6984, 10.1371/journal.pone.0006984
Condos, R. & Schluger, N. W. Cytokine-Based Approaches to the Treatment of Multidrug-Resistant Tuberculosis. BioDrugs11, 165–173 (1999).
Johnson, B. J. et al. Clinical and immune responses of tuberculosis patients treated with low-dose IL-2 and multidrug therapy. Cytokines Mol. Ther.1, 185–196 (1995).
Pedral-Sampaio, D. B. et al. Use of Rhu-GM-CSF in Pulmonary Tuberculosis Patients: Results of a Randomized Clinical Trial. Braz J Infect Dis. 7, 245–252 (2003).
Johnson, 2003, Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis, Am. J. Respir. Crit. Care Med., 168, 185, 10.1164/rccm.200211-1359OC
Sakai, 2016, CD4 T cell-derived IFN-γ plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease, PLoS Pathog., 12, e1005667, 10.1371/journal.ppat.1005667
Roca, 2013, TNF dually mediates resistance and susceptibility to mycobacteria through mitochondrial reactive oxygen species, Cell, 153, 521, 10.1016/j.cell.2013.03.022
Blackmore, 2008, Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes, Clin. Infect. Dis., 47, e83, 10.1086/592695
Wallis, R. S., van Vuuren, C. & Potgieter, S. Adalimumab treatment of life-threatening tuberculosis. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am.48, 1429–1432 (2009).
Wallis, 2008, Tumour necrosis factor antagonists: structure, function, and tuberculosis risks, Lancet Infect. Dis., 8, 601, 10.1016/S1473-3099(08)70227-5
Zhang, 2017, Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials, BMJ Open, 7, e012567, 10.1136/bmjopen-2016-012567
Rivero-Lezcano, 2008, Cytokines as Immunomodulators in Tuberculosis Therapy, Recent Patents on Anti-Infective Drug Discovery, 3, 168, 10.2174/157489108786242332
Parihar, 2014, Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation, J. Infect. Dis., 209, 754, 10.1093/infdis/jit550
Skerry, 2014, Simvastatin increases the in vivo activity of the first-line tuberculosis regimen, Journal of Antimicrobial Chemotherapy, 69, 2453, 10.1093/jac/dku166
Lobato, 2014, Statins increase rifampin Mycobactericidal effect, Antimicrob. Agents Chemother., 58, 5766, 10.1128/AAC.01826-13
Kyrklund, 2000, Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations, Clin. Pharmacol. Ther., 68, 592, 10.1067/mcp.2000.111414
Rao, 2019, Improving treatment outcomes for MDR-TB—novel host-directed therapies and personalised medicine of the future, Int. J. Infect. Dis., 80, S62, 10.1016/j.ijid.2019.01.039
Skrahin, 2014, Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial, Lancet Respir. Med., 2, 108, 10.1016/S2213-2600(13)70234-0
Skrahin, 2016, Potential role of autologous mesenchymal stromal cells in the treatment of multidrug and extensively drug-resistant tuberculosis, Eur. Respir. J., 48, PA1919
Mizukami, A. & Swiech, K. Mesenchymal stromal cells: from discovery to manufacturing and commercialization. Stem Cells Int. 2018 (2018).
Iannaccone, 2014, Host-directed therapy of tuberculosis: what is in it for microRNA?, Expert Opin. Ther. Targets, 18, 491, 10.1517/14728222.2014.897696
Desikan, 2018, Host-targeted therapy for tuberculosis: time to revisit the concept, Indian J. Med. Res., 147, 233, 10.4103/ijmr.IJMR_652_17
Paik, 2019, Autophagy: a new strategy for host-directed therapy of tuberculosis, Virulence, 10, 448, 10.1080/21505594.2018.1536598
Stanley, 2014, Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth, PLoS Pathog., 10, e1003946, 10.1371/journal.ppat.1003946
Zhang, 2017, Antimycobacterial and anti-inflammatory mechanisms of baicalin via induced autophagy in macrophages infected with mycobacterium tuberculosis, Front. Microbiol., 8, 2142, 10.3389/fmicb.2017.02142
Juarez, 2016, Loperamide restricts intracellular growth of Mycobacterium tuberculosis in lung macrophages, Am. J. Respir. Cell Mol. Biol., 55, 837, 10.1165/rcmb.2015-0383OC
Kim, 2012, Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action, Cell Host Microbe, 11, 457, 10.1016/j.chom.2012.03.008
Choi, 2018, Ambroxol induces autophagy and potentiates rifampin antimycobacterial activity, Antimicrob. Agents Chemother., 62, e01018, 10.1128/AAC.01019-18
Walker, 2012, Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases, Am. J. Respir. Crit. Care Med., 185, 989, 10.1164/rccm.201110-1769OC
Ong, 2015, Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis, PLoS Pathog., 11, e1004917, 10.1371/journal.ppat.1004917
Nemes, 2018, Prevention of M. tuberculosis infection with H4: IC31 vaccine or BCG revaccination, N. Engl. J. Med., 379, 138, 10.1056/NEJMoa1714021
Kleinnijenhuis, 2012, Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes, Proc. Natl. Acad. Sci. USA, 109, 17537, 10.1073/pnas.1202870109
Joosten, 2018, Mycobacterial growth inhibition is associated with trained innate immunity, Journal of Clinical Investigation, 128, 1837, 10.1172/JCI97508
Goodridge, 2016, Harnessing the beneficial heterologous effects of vaccination, Nat. Rev. Immunol., 16, 392, 10.1038/nri.2016.43
Benn, 2013, A small jab—a big effect: nonspecific immunomodulation by vaccines, Trends Immunol., 34, 431, 10.1016/j.it.2013.04.004
Tanner, 2019, The humoral immune response to BCG vaccination, Front. Immunol., 10, 1317, 10.3389/fimmu.2019.01317
Koeken, V. A., Verrall, A. J., Netea, M. G., Hill, P. C. & van Crevel, R. Trained innate immunity and resistance to Mycobacterium tuberculosis infection. Clin. Microbiol. Infect. In press (2019).
Schaible, 2017, Strategies to improve vaccine efficacy against Tuberculosis by Targeting innate immunity, Front. Immunol., 8, 1755, 10.3389/fimmu.2017.01755
Vilaplana, 2013, Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis, J. Infect. Dis., 208, 199, 10.1093/infdis/jit152
Eisen, 2013, Low-dose aspirin and ibuprofen's sterilizing effects on mycobacterium tuberculosis suggest safe new adjuvant therapies for tuberculosis, J. Infect. Dis., 208, 1925, 10.1093/infdis/jit476
Byrne, 2006, Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis, J. Antimicrob. Chemother., 59, 313, 10.1093/jac/dkl486
Misra, 2010, Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial, J. Neurol. Sci., 293, 12, 10.1016/j.jns.2010.03.025
Schoeman, 2011, The role of aspirin in childhood tuberculous meningitis, J. Child Neurol., 26, 956, 10.1177/0883073811398132
Peres-Buzalaf, 2011, Control of experimental pulmonary tuberculosis depends more on immunostimulatory leukotrienes than on the absence of immunosuppressive prostaglandins, Prostaglandins Leukot. Essent. Fatty Acids, 85, 75, 10.1016/j.plefa.2011.04.024
Kalle, 2011, Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor, Antimicrob. Agents Chemother., 55, 439, 10.1128/AAC.00735-10
Salunke, 2015, Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore, Bioorg. Med. Chem., 23, 1935, 10.1016/j.bmc.2015.03.041
Semba, 2007, Micronutrient supplements and mortality of HIV-infected adults with pulmonary TB: a controlled clinical trial, Int. J. Tuberc. Lung Dis., 11, 854
Martineau, 2011, High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial, The Lancet, 377, 242, 10.1016/S0140-6736(10)61889-2
Daley, 2015, Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial, Lancet Infect. Dis., 15, 528, 10.1016/S1473-3099(15)70053-8
Kamen, 2010, Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity, J. Mol. Med., 88, 441, 10.1007/s00109-010-0590-9
Grange, 1985, A study of vitamin D levels in Indonesian patients with untreated pulmonary tuberculosis, Tubercle, 66, 187, 10.1016/0041-3879(85)90035-2
Ralph, 2013, L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial, PloS One, 8, e70032, 10.1371/journal.pone.0070032
Schön, 2003, Arginine as an adjuvant to chemotherapy improves clinical outcome in active tuberculosis, Eur. Respir. J., 21, 483, 10.1183/09031936.03.00090702
Mily, 2015, Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial, PLoS ONE, 10, e0138340, 10.1371/journal.pone.0138340
Coussens, 2015, Phenylbutyrate is bacteriostatic against Mycobacterium tuberculosis and regulates the macrophage response to infection, synergistically with 25-hydroxy-vitamin D3, PLoS Pathog., 11, e1005007, 10.1371/journal.ppat.1005007
Armijos, 2010, Adjunctive micronutrient supplementation for pulmonary tuberculosis, Salud Pública México, 52, 185, 10.1590/S0036-36342010000300001
Range, 2006, The effect of multi-vitamin/mineral supplementation on mortality during treatment of pulmonary tuberculosis: a randomised two-by-two factorial trial in Mwanza, Tanzania, Br. J. Nutr., 95, 762, 10.1079/BJN20051684
Overbeck, 2008, Modulating the immune response by oral zinc supplementation: a single approach for multiple diseases, Arch. Immunol. Ther. Exp. (Warsz.), 56, 15, 10.1007/s00005-008-0003-8
Arjanova, 2009, Impact of adjunct immunotherapy with multi-herbal supplement Dzherelo (Immunoxel) on treatment outcomes in end-stage TB/HIV patients, J. Antivir. Antiretrovir., 1, 86
Zaiteva, 2009, Efficacy and safety of phytoconcentrate Dzherelo (Immunoxel) in treatment of patients with multi-drug resistant TB (MDR-TB) in comparison to standartd chemotherapy, Res. J. Med. Sci., 3, 36
Nikolaeva, 2008, Cytokine profiles of HIV patients with pulmonary tuberculosis resulting from adjunct immunotherapy with herbal phytoconcentrates Dzherelo and Anemin, Cytokine, 44, 392, 10.1016/j.cyto.2008.10.009
Efremenko, 2012, Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients, Immunotherapy, 4, 273, 10.2217/imt.11.176
Hakim, 2000, Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients, Heart, 84, 183, 10.1136/heart.84.2.183
Elliott, 1992, Use of Prednisolone in the Treatment of HIV-positive Tuberculosis Patients, QJM Int. J. Med., 85, 855
Bilaçeroğlu, 1999, Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial, Int. J. Tuberc. Lung Dis., 3, 47
Bell, 1960, Prednisolone in the treatment of acute extensive pulmonary tuberculosis in West Africans, Tubercle, 41, 341, 10.1016/S0041-3879(60)80036-0
Rock, 2005, Mycobacterium tuberculosis-induced cytokine and chemokine expression by human microglia and astrocytes: effects of dexamethasone, J. Infect. Dis., 192, 2054, 10.1086/498165
Girgis, 1991, Dexamethasone adjunctive treatment for tuberculous meningitis, Pediatr. Infect. Dis. J., 10, 179, 10.1097/00006454-199103000-00002
Kesavan, 2005, Effects of dexamethasone and transient malnutrition on rabbits infected with aerosolized Mycobacterium tuberculosis CDC1551, Infect. Immun., 73, 7056, 10.1128/IAI.73.10.7056-7060.2005
Green, 2009, Dexamethasone, cerebrospinal fluid matrix metalloproteinase concentrations and clinical outcomes in tuberculous meningitis, PLoS ONE, 4, e7277, 10.1371/journal.pone.0007277
Török, 2011, Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents, PLoS ONE, 6, e27821, 10.1371/journal.pone.0027821
Donovan, 2018, Adjunctive dexamethasone for the treatment of HIV-infected adults with tuberculous meningitis (ACT HIV): study protocol for a randomised controlled trial, Wellcome Open Res., 3, 31, 10.12688/wellcomeopenres.14006.2
Thwaites, 2004, Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults, N. Engl. J. Med., 351, 1741, 10.1056/NEJMoa040573
Banerjee, 2014, Statin therapy may prevent development of tuberculosis in diabetic state, Med. Hypotheses, 83, 88, 10.1016/j.mehy.2014.04.002
Eiter, 2009, Gold (I) analogues of a platinum-acridine antitumor agent are only moderately cytotoxic but show potent activity against Mycobacterium tuberculosis, J. Med. Chem., 52, 6519, 10.1021/jm9012856
Harbut, 2015, Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis, Proc. Natl. Acad. Sci. USA, 112, 4453, 10.1073/pnas.1504022112
Subbian, 2016, Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis, Front. Immunol., 7, 238, 10.3389/fimmu.2016.00238
Subbian, 2011, Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs, PLoS Pathog., 7, e1002262, 10.1371/journal.ppat.1002262
Koo, 2011, Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice, PLoS ONE, 6, e17091, 10.1371/journal.pone.0017091
Attri, 2000, Isoniazid- and rifampicin-induced oxidative hepatic injury-protection by N-acetylcysteine, Hum. Exp. Toxicol., 19, 517, 10.1191/096032700674230830
Condos, 1997, Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol, Lancet Lond. Engl., 349, 1513, 10.1016/S0140-6736(96)12273-X
Giosuè, 2000, Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis, Eur. Cytokine Netw., 11, 99
Suárez-Méndez, 2004, Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study, BMC Infect. Dis., 4, 10.1186/1471-2334-4-44
Grahmann, 2008, A new protocol for multiple inhalation of IFN- successfully treats MDR-TB: a case study, Int. J. Tuberc. Lung Dis., 12, 636
Wallis, 2004, A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS Lond. Engl., 18, 257
Mayanja-Kizza, 2005, Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda, J. Infect. Dis., 191, 856, 10.1086/427995
Allen, 2004, Effect of neutralizing transforming growth factor β1 on the immune response against Mycobacterium tuberculosis in guinea pigs, Infect. Immun., 72, 1358, 10.1128/IAI.72.3.1358-1363.2004
Datta, 2015, Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery, Proc. Natl. Acad. Sci. USA, 112, 1827, 10.1073/pnas.1424563112
Oehlers, 2015, Interception of host angiogenic signalling limits mycobacterial growth, Nature, 517, 612, 10.1038/nature13967
Johnson, 1997, rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo, Tuber. Lung Dis., 78, 195, 10.1016/S0962-8479(97)90026-5
Buccheri, 2007, IL-4 depletion enhances host resistance and passive IgA protection against tuberculosis infection in BALB/c mice, Eur. J. Immunol., 37, 729, 10.1002/eji.200636764
Roy, 2008, Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection, Tuberc. Edinb. Scotl., 88, 197
Singh, 2011, Co-administration of IL-1+IL-6+TNF-α with Mycobacterium tuberculosis infected macrophages vaccine induces better protective T cell memory than BCG, PLoS ONE, 6, e16097, 10.1371/journal.pone.0016097
Maeurer, 2000, Interleukin-7 or Interleukin-15 Enhances Survival of Mycobacterium tuberculosis-Infected Mice, Infect. Immun., 68, 2962, 10.1128/IAI.68.5.2962-2970.2000
Silva, 2001, Blocking the receptor for IL-10 improves antimycobacterial chemotherapy and vaccination, J. Immunol., 167, 1535, 10.4049/jimmunol.167.3.1535
Flynn, 1995, IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection, J. Immunol., 155, 2515, 10.4049/jimmunol.155.5.2515
Greinert, 2001, Interleukin-12 as successful adjuvant in tuberculosis treatment, Eur. Respir. J., 17, 1049, 10.1183/09031936.01.17510490
Umemura, 2003, Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination, Infect. Immun., 71, 6045, 10.1128/IAI.71.10.6045-6048.2003
Happel, 2005, Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs, Infect. Immun., 73, 5782, 10.1128/IAI.73.9.5782-5788.2005
Ma, 2011, Interleukin 24 as a novel potential cytokine immunotherapy for the treatment of Mycobacterium tuberculosis infection, Microbes Infect., 13, 1099, 10.1016/j.micinf.2011.06.012
Liu, 2017, IL-37 Confers protection against Mycobacterial infection involving suppressing inflammation and modulating T cell activation, PLoS ONE, 12, e0169922, 10.1371/journal.pone.0169922
Shen, 2015, The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis, Arch. Med. Sci. AMS, 11, 584, 10.5114/aoms.2015.52362
Tan, 2017, Clinical and immunological effects of rhIL-2 therapy in eastern Chinese patients with multidrug-resistant tuberculosis, Sci. Rep., 7, 10.1038/s41598-017-18200-5